{"disease":{"id":"myeloid-malignancy","name":"myeloid malignancy"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02958462","title":"Pre-myeloid Cancer and Bone Marrow Failure Clinic Study","phase":"NA","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04466137","title":"Phase 3 Study to Evaluate the Safety and Efficacy of YPEG-rhG-CSF in Malignancies Receiving Chemotherapy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":398,"lead_sponsor_name":"Xiamen Amoytop Biotech Co., Ltd.","has_results":false},{"nct_id":"NCT06090513","title":"Molecular Services and EMR-Lab Integration Application (ELIA) for Reducing Healthcare Disparities in Cancer Patients","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Bien-Willner Physicians Group PA","has_results":false},{"nct_id":"NCT05875805","title":"A Telehealth Advance Care Planning Intervention","phase":"NA","overall_status":"RECRUITING","enrollment_count":207,"lead_sponsor_name":"University of Rochester","has_results":false},{"nct_id":"NCT04662892","title":"An Analysis to Estimate Febrile Neutropenia (FN) in Patients Receiving Udenyca","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Coherus Oncology, Inc.","has_results":false},{"nct_id":"NCT07263074","title":"Considering alloHCT: Opportunities for Patient Reflection During Decision-Making Via Digital Stories","phase":"NA","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"University of Rochester","has_results":false},{"nct_id":"NCT06378437","title":"A Study of GLB-001 in Patients With Myeloid Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":108,"lead_sponsor_name":"Hangzhou GluBio Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT05841771","title":"Hypomethylating Agent and Venetoclax After Allo-HSCT in Patients With High-risk Myeloid Malignancies.","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":78,"lead_sponsor_name":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT06621212","title":"Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AML","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":72,"lead_sponsor_name":"First Affiliated Hospital of Zhejiang University","has_results":false},{"nct_id":"NCT01822509","title":"Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":71,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02949427","title":"The Oronasal Microbiota in Pediatric Oncology Patients","phase":"","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT04214860","title":"APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":51,"lead_sponsor_name":"Aprea Therapeutics","has_results":true},{"nct_id":"NCT03560882","title":"A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Joaquina Baranda","has_results":false},{"nct_id":"NCT05583175","title":"Venetoclax Plus RIC Regimen Allo-HSCT for Elderly Patients With High-risk Myeloid Malignancies","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Xianmin Song, MD","has_results":false},{"nct_id":"NCT06594445","title":"HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":45,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT03850418","title":"Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":43,"lead_sponsor_name":"Henry Ford Health System","has_results":false},{"nct_id":"NCT02333162","title":"Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant","phase":"PHASE1","overall_status":"SUSPENDED","enrollment_count":30,"lead_sponsor_name":"University of Chicago","has_results":false},{"nct_id":"NCT03082677","title":"Study of Ixazomib to Prevent Recurrent or Late Acute and Chronic Graft-versus-Host Disease 1-year After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":true},{"nct_id":"NCT05455294","title":"Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":16,"lead_sponsor_name":"Jacqueline Garcia, MD","has_results":false},{"nct_id":"NCT03961919","title":"Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic Transplant","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Ciceri Fabio","has_results":false},{"nct_id":"NCT05350163","title":"T-cell Receptor α/β Depleted Donor Lymphocyte Infusion","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":11,"lead_sponsor_name":"Guenther Koehne","has_results":true},{"nct_id":"NCT04906031","title":"Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 Mutations","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":5,"lead_sponsor_name":"First Affiliated Hospital of Jinan University","has_results":false},{"nct_id":"NCT05579769","title":"Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":true},{"nct_id":"NCT03272633","title":"Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies","phase":"EARLY_PHASE1","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"Rutgers, The State University of New Jersey","has_results":true},{"nct_id":"NCT03878524","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT06543511","title":"MyeloGen: Germline Testing for Predisposition to Myeloid Malignancies","phase":"NA","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT05968170","title":"TCRαβ/CD19 Depletion of Stem Cell Grafts for Transplant","phase":"NA","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Neena Kapoor, M.D.","has_results":false}],"total":27},"guidelines":[],"source":"Drug Landscape verified database"}